Efficacy, Safety, and Tolerability Considerations in the Novel Treatment of Major Depressive Disorder

Depressive Disorder ◽

The Novel ◽

Major Depressive ◽

Cytokine alterations and cognitive impairment in major depressive disorder: From putative mechanisms to novel treatment targets

Progress in Neuro-Psychopharmacology and Biological Psychiatry ◽

10.1016/j.pnpbp.2017.04.021 ◽

2018 ◽

Vol 80 ◽

pp. 177-188 ◽

Cited By ~ 25

Author(s):

Błażej Misiak ◽

Jan Aleksander Beszłej ◽

Kamila Kotowicz ◽

Monika Szewczuk-Bogusławska ◽

Jerzy Samochowiec ◽

...

Keyword(s):

Cognitive Impairment ◽

Depressive Disorder ◽

Major Depressive ◽

Treatment Targets ◽

Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder

Journal of Clinical Psychopharmacology ◽

10.1097/jcp.0b013e31823608ca ◽

2011 ◽

Vol 31 (6) ◽

pp. 727-733 ◽

Cited By ~ 49

Author(s):

Emiliangelo Ratti ◽

Kevin Bellew ◽

Paolo Bettica ◽

Heather Bryson ◽

Stefano Zamuner ◽

...

Keyword(s):

Depressive Disorder ◽

Receptor Antagonist ◽

The Novel ◽

Nk1 Receptor ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Nk1 Receptor Antagonist

Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder: A Randomized, Double-Blind Comparison With Sertraline

Yearbook of Psychiatry and Applied Mental Health ◽

10.1016/j.ypsy.2010.10.061 ◽

2011 ◽

Vol 2011 ◽

pp. 250-251

Author(s):

J.C. Ballenger

Keyword(s):

Depressive Disorder ◽

Activity Cycle ◽

Anxiety Symptoms ◽

The Novel ◽

Major Depressive ◽

Double Blind ◽

Blind Comparison ◽

Rest Activity

The Role of Systemic Inflammation in Major Depressive Disorder and Implications for Novel Treatment Approaches

Journal of Affective Disorders ◽

10.1016/j.jad.2018.10.308 ◽

2019 ◽

Vol 254 ◽

pp. 139-140

Author(s):

B. Christopher Frueh ◽

Summer G. Danner ◽

Alok Madan ◽

Benjamin Weinstein ◽

Elizabeth Newlin ◽

...

Keyword(s):

Depressive Disorder ◽

Systemic Inflammation ◽

Major Depressive ◽

Treatment Approaches ◽

P.245 Intranasal administration of neuropeptide Y; development of a novel treatment for major depressive disorder

European Neuropsychopharmacology ◽

10.1016/j.euroneuro.2020.09.184 ◽

2020 ◽

Vol 40 ◽

pp. S139-S140

Author(s):

A.A. Mathé ◽

E. Berg ◽

M. Michaneck ◽

D.S. Charney ◽

J.W. Murrough

Keyword(s):

Depressive Disorder ◽

Neuropeptide Y ◽

Intranasal Administration ◽

Major Depressive ◽

Concerns about data reporting and interpretation in “Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial”

Journal of Psychiatric Research ◽

10.1016/j.jpsychires.2012.02.002 ◽

2012 ◽

Vol 46 (5) ◽

pp. 692-693 ◽

Cited By ~ 4

Author(s):

David M. Marks ◽

Jonathan S. Abramowitz ◽

Glen I. Spielmans

Keyword(s):

Depressive Disorder ◽

Reuptake Inhibitor ◽

Controlled Trial ◽

The Novel ◽

Major Depressive ◽

Double Blind ◽

Data Reporting ◽

Double Blind Placebo

Novel Treatment Strategies for Major Depressive Disorder: Investigating Ketamine’s Antidepressant Effects and the Role of the c-Jun N-Terminal Kinase Pathway

10.22215/etd/2019-13740 ◽

2019 ◽

Author(s):

Melanie Clarke

Keyword(s):

Depressive Disorder ◽

Treatment Strategies ◽

Major Depressive ◽

Novel Treatment ◽

Antidepressant Effects ◽

Novel Treatment Strategies ◽

Kinase Pathway

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial

Journal of Psychiatric Research ◽

10.1016/j.jpsychires.2011.09.003 ◽

2012 ◽

Vol 46 (1) ◽

pp. 64-71 ◽

Cited By ~ 52

Author(s):

Pierre Tran ◽

Phil Skolnick ◽

Pal Czobor ◽

N.Y. Huang ◽

Mark Bradshaw ◽

...

Keyword(s):

Depressive Disorder ◽

Reuptake Inhibitor ◽

Controlled Trial ◽

The Novel ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis

General Hospital Psychiatry ◽

10.1016/j.genhosppsych.2015.01.003 ◽

2015 ◽

Vol 37 (2) ◽

pp. 178-184 ◽

Cited By ~ 54

Author(s):

Ellen E. Lee ◽

Megan P. Della Selva ◽

Anson Liu ◽

Seth Himelhoch

Keyword(s):

Systematic Review ◽

Depressive Disorder ◽

Bipolar Depression ◽

Meta Analysis ◽

Major Depressive ◽

Treatment of Major Depressive Disorder by Transcranial Random Noise Stimulation: Case Report of a Novel Treatment

Biological Psychiatry ◽

10.1016/j.biopsych.2012.02.009 ◽

2012 ◽

Vol 72 (4) ◽

pp. e9-e10 ◽

Cited By ~ 18

Author(s):

Herng-Nieng Chan ◽

Angelo Alonzo ◽

Donel M. Martin ◽

Michael Player ◽

Philip B. Mitchell ◽

...

Keyword(s):

Transcranial Random Noise Stimulation

Case Report ◽

Depressive Disorder ◽

Random Noise ◽

Major Depressive ◽

Novel Treatment ◽